Wildlife and nature

Animal shelters and rescues

Theater and dance

Rivers, parks and trails

Hunger and food

Schools and learning

Housing and homelessness

Community health

Mental health

Mentoring and foster care

Legal help and rights

Jobs and money help

Atlanta

The Triangle

Everywhere

The Collective Workshop

Royal Animal Refuge

Asian Americans Advancing Justice-Atlanta

Georgia Advancing Communities Together

Atlanta Writers Club

Cobb Collaborative

Bosleys Place

Jewish Fertility Foundation

Dr. Ken Culver

Kirk Smith

Summer Farmen

Christina Weber

Nancee Pronsati

Teresa Wiant

Jeffrey Sturm

Greg Wehn

Duncan Preece

Amanda Bialack-Stewart

Debbi Martinez

Yvonne Diaz

Marc Muskavitch

Thomas Carroll

Dr. Mark Awad

Dr. Ross Camidge

Beau Bolton

Jaden Southard

John Pender

Myna Kota

Merita Carroll

Roberta Plantak

Katie Delaney

Sadia Yaakov

Programs

Events

About

ALKtALK

🔬 Help Advance CAR T-Cell Research for Oncogene-Driven Lung Cancer On October 18, over 200 patients, care partners, and advocates from the ALK-positive, EGFR, HER2, and broader oncogene-driven lung cancer communities joined ALKtALK, in collaboration with EGFR Resisters, to hear Dr. Kyle Concannon from the University of Colorado Anschutz Medical Campus. He shared his work on active-conformation EGFR-specific (ACES) CAR T cells, a new approach designed to find and attack the cancer cells that survive targeted therapy. For many of us, that is the question that matters most. ALK inhibitors have given us more time than ever before, but resistance remains the reality we all live with. CAR T-cell therapy has already changed what is possible for some blood cancers. Dr. Concannon’s research asks whether engineered immune cells could do the same for oncogene-driven lung cancer, and possibly work alongside the targeted therapies we already rely on. The ACES program includes ALK-positive and EGFR arms, and our communities have the chance to help move it forward. Research at this stage is needed to build the evidence for a first clinical trial. This research is still early. That is exactly why patient-funded support matters: early-stage science is often the hardest to fund, and our communities can help shape what gets studied and how quickly. Together, we can help create more possibilities for people living with oncogene-driven lung cancer. Watch the ALKtALK replay to learn more about Dr. Concannon's research and how our communities can help move this work forward. ▶️ https://youtu.be/30skcFExCPA?si=KV6bYX9ZGY0gB63X Stay informed. Become empowered.

🧬 Could CAR T-cell therapy offer a new way to treat lung cancer? It’s already transforming treatment for some blood cancers. Now researchers are exploring whether CAR T-cell therapy could help tackle lung cancer, including cancers that develop resistance to targeted therapies. Join ALK Positive and EGFR Resisters tomorrow (Sunday, Oct 18th) for a special joint ALKtALK with Dr Kyle Concannon, thoracic oncologist and physician-scientist at the University of Colorado Anschutz Medical Campus. Dr Concannon and team are developing ACES CAR T cells, an experimental approach with potential applications across ALK, EGFR, HER2 and other oncogene-driven lung cancers. 💙 What makes this research particularly exciting? It explores whether specially engineered immune cells could offer an entirely different way to target cancer cells. We’ll discuss how the science works, where the research stands today and what needs to happen before the first clinical trial. 🎤 Plus, a live Q&A with Dr Concannon! Bring your questions and hear directly from the scientist developing this approach. 📅 Sunday, October 18 ⏰ 7 p.m. ET 🔗 Register through the link in our bio! Many patient communities. One shared goal: more treatment options for everyone. 💙 #ALKPositive #EGFR #LungCancer #CARTCellTherapy

🎥 The ALKtALK Replay is Now Available! What’s new in ALK-positive cancer research, and what could it mean for you? In our latest ALKtALK, Dr. Ken Culver, Executive Director and Medical Director of ALK Positive, shares updates on new clinical trials, emerging research, and projects supported by or connected to the ALK-positive community. 🔬 From new treatment approaches to ongoing research efforts, learn what’s happening in ALK-positive cancer research and how this work could help create more options for patients. 💚 Plus, get a special preview of More Research = More Dreams, our upcoming Lung Cancer Awareness Month campaign, and discover how you can get involved this November! ▶️ Watch the full ALKtALK replay now on our YouTube channel: https://www.youtube.com/watch?v=r3ocrSEb-jc #ALKPositive #ALKtALK #LungCancerAwarenessMonth #MoreResearchMoreDreams

What does survivorship mean when you're living with ALK-positive cancer? Survivorship is about more than a diagnosis or treatment. It's about living, adapting, and finding ways to maintain quality of life along the way. In this clip from our Season 7 premiere of ALKtALK, Dr. Eric Singhi, thoracic medical oncologist at MD Anderson Cancer Center, shares his perspective on what cancer survivorship means for the ALK-positive community. In the full conversation, Dr. Singhi also discusses building a multidisciplinary care team, advances in lung cancer research, and practical questions about TKIs, cancer progression, vaccines, and more. Whether you're newly diagnosed or have been living with ALK-positive cancer for years, this conversation offers valuable information and perspective on navigating life after diagnosis. 🎥 Watch the full ALKtALK replay: https://youtu.be/aIVlb1OiWxU #ALKPositive #ALKtALK #CancerSurvivorship #LifeWithALKPositiveCancer

🔬 What’s next in ALK-positive cancer research? Join us Sunday, Oct. 4 at 7 PM ET for a special ALKtALK with Dr. Ken Culver exploring the research, clinical trials, and collaborations helping shape what comes next for people living with ALK-positive cancer. Dr. Culver will share updates on: • New and emerging ALK research • Clinical trials and expanding trial opportunities • A new study exploring Zepbound for lorlatinib-associated weight gain • The Global ALK Alliance and growing research collaborations We’ll also share an early preview of Lung Cancer Awareness Month and how our community can get involved this November. 💜 Whether you’re newly diagnosed, exploring future treatment options, or simply want to stay informed, bring your questions and join us live. 📅 Sunday, Oct. 4 ⏰ 7 PM ET 🔗 https://alkpositive.org/event/alktalk-oct4/ Can’t join live? The recording will be available afterward on our YouTube channel.

ALKtALK is back for Season 7! We could not be more excited to kick off Season 7 of ALKtALK with the one and only Dr. Eric Singhi of MD Anderson Cancer Center! ALKtALK Season 7 Premiere: A Fireside Chat with Dr. Eric Singhi Sunday, September 27 7:00 p.m. ET Live on Zoom | Recorded and available on YouTube You may know Dr. Singhi from social media as @lungoncdoc, where he is known for making complex cancer information accessible, engaging, and actually understandable. If you're not already following him, you should be! We'll cover the latest updates from the World Conference on Lung Cancer, while also taking it back to the basics with real-life topics that matter when you're living with ALK-positive cancer. And we want your questions, too. Bring the things you've wondered about, forgot to ask at your last appointment, or simply want an expert to weigh in on. Whether you are newly diagnosed, have been living with ALK-positive cancer for years, or are a care partner or loved one, this conversation is for you. Learn more and join the session here: https://alkpositive.org/event/alktalk-dr-eric-singhi/ #ALKtALK #ALKPositive #PatientEducation

ALK Positive Essentials

Cancer research

Treatment options

Living with cancer

Collective

Collections

Account

ALKtALK

More collections